- Home
- ATAI vs CLYM Comparison
ATAI vs CLYM Comparison
Compare ATAI & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- CLYM
- Stock Information
- Founded
- ATAI 2018
- CLYM 2018
- Country
- ATAI Germany
- CLYM United States
- Employees
- ATAI N/A
- CLYM N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- ATAI Health Care
- CLYM
- Exchange
- ATAI Nasdaq
- CLYM NYSE
- Market Cap
- ATAI 214.8M
- CLYM 201.7M
- IPO Year
- ATAI 2021
- CLYM 2021
- Fundamental
- Price
- ATAI $1.61
- CLYM $3.05
- Analyst Decision
- ATAI Strong Buy
- CLYM
- Analyst Count
- ATAI 4
- CLYM 0
- Target Price
- ATAI $9.00
- CLYM N/A
- AVG Volume (30 Days)
- ATAI 2.3M
- CLYM 310.8K
- Earning Date
- ATAI 11-13-2024
- CLYM 11-12-2024
- Dividend Yield
- ATAI N/A
- CLYM N/A
- EPS Growth
- ATAI N/A
- CLYM N/A
- EPS
- ATAI N/A
- CLYM N/A
- Revenue
- ATAI $331,000.00
- CLYM N/A
- Revenue This Year
- ATAI $44.72
- CLYM N/A
- Revenue Next Year
- ATAI N/A
- CLYM N/A
- P/E Ratio
- ATAI N/A
- CLYM N/A
- Revenue Growth
- ATAI N/A
- CLYM N/A
- 52 Week Low
- ATAI $1.03
- CLYM $2.35
- 52 Week High
- ATAI $2.85
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- ATAI 61.07
- CLYM N/A
- Support Level
- ATAI $1.53
- CLYM N/A
- Resistance Level
- ATAI $1.95
- CLYM N/A
- Average True Range (ATR)
- ATAI 0.22
- CLYM 0.00
- MACD
- ATAI 0.03
- CLYM 0.00
- Stochastic Oscillator
- ATAI 62.22
- CLYM 0.00
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.